Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Risk Reports
Published in: Current Cardiovascular Risk Reports 2/2011

Open Access 01-04-2011

The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe

Authors: Agata Bielecka-Dabrowa, Wilbert S. Aronow, Jacek Rysz, Maciej Banach

Published in: Current Cardiovascular Risk Reports | Issue 2/2011

Login to get access

Abstract

Hypertension is a progressive cardiovascular syndrome that arises from many differing, but interrelated, etiologies. Hypertension is the most prevalent cardiovascular disorder, affecting 20% to 50% of the adult population in developed countries. Arterial hypertension is a major risk factor for cardiovascular diseases and death. Epidemiologic data have shown that control of hypertension is achieved in only a small percentage of hypertensive patients. Findings from the World Health Organization project Monitoring Trends and Determinants in Cardiovascular Diseases (MONICA) showed a remarkably high prevalence (about 65%) of hypertension in Eastern Europeans. There is virtually no difference however, between the success rate in controlling hypertension when comparing Eastern and Western European populations. Diagnosing hypertension depends on both population awareness of the dangers of hypertension and medical interventions aimed at the detecting elevated blood pressure, even in asymptomatic patients. Medical compliance with guidelines for the treatment of hypertension is variable throughout Eastern Europe. Prevalence of hypertension increases with age, and the management of hypertension in elderly is a significant problem. The treatment of hypertension demands a comprehensive approach to the patient with regard to cardiovascular risk and individualization of hypertensive therapy.
Literature
1.
Bruce Goldfarb. ASH Panel Proposes New Hypertension Definition. 2005; 2: 1–7.
2.
From the Centers for Disease Control and Prevention. Decline in deaths from heart disease and stroke—United States, 1990–1999. JAMA 1999; 282: 724–6.CrossRef
3.
Mancia G, Grassi G. The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. Ther Adv Cardiovasc Dis. 2008;2(1):5–12.PubMedCrossRef
4.
Guidelines Subcommittee, World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83.
5.
Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206–1252.PubMedCrossRef
6.
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58. These are the current guidelines of European Society of Hypertension, and they recommend new borderline issues on hypertension diagnosis and management. PubMedCrossRef
7.
Marques-Vidal P, Tuomilehto J. Hypertens awareness, treatment and control in the community: is the “rule of halves” still valid? J Hum Hypertens 1997; 11: 213–20.PubMedCrossRef
8.
Mancia G, Sega R, Milesi C, Cesana S, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454–7.PubMedCrossRef
9.
MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74.PubMedCrossRef
10.
Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–6.PubMedCrossRef
11.
Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713–24.PubMedCrossRef
12.
Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992; 268: 3085–91.PubMedCrossRef
13.
National High Blood Pressure Education Program Working Group. Arch Intern Med. 1993;153:186–208.
14.
Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5.PubMedCrossRef
15.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.PubMedCrossRef
16.
Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–7.PubMedCrossRef
17.
Kjeldsen SE, Reims HM, Fagard R and Mancia G. Hypertension. In: Camm AJ, Luscher TF, Serruys PW. The ESC textbook of cardiovascular medicine. P 271–300.
18.
Kannel WB. Update on hypertension as a cardiovascular risk factor. In: Manual of Hypertension. Mancia G (ed.). Churchill Livingstone: London 2002; 4–19.
19.
Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.PubMedCrossRef
20.
Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A; APROS Investigators. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20: 1307–14.PubMedCrossRef
21.
Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–62.PubMed
22.
• Cífková R. Epidemiology and risk of hypertension. Arch Med Sci 2009; 5, 2A: S 199–S 211. This article presents the current data on epidemiology and risk of hypertension, including data from Eastern European countries.
23.
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–9.PubMedCrossRef
24.
Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289: 2363–9.PubMedCrossRef
25.
26.
Zdrojewski T, Bandosz P, Szpakowski Pet al. The prevalence of major risk factors for diseases of the cardiovascular system in Poland. Test results NATPOL PLUS. Kardiol. Pol. 2004; 61(supl. IV): 15–17.
27.
Tykarski A, Posadzy-Małaczyńska A, Wyrzykowski B et al. Prevalence of hypertension and the effectiveness of its treatment in adults in our country. Results of WOBASZ study. Kardiol. Pol. 2005; 63: S614–S619.PubMed
28.
Kobalava ZhD, Kotovskaia IuV, Starostina EG et al. Problems of a physician-patient interaction and control of arterial hypertension in Russia. Main results of scientific-practical program ARGUS-2. Kardiologiia. 2007;47(3):38–47.PubMed
29.
Cífková R, Skodová Z, Lánská V, et al. Trends in blood pressure levels, prevalence, awareness, treatment and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479–85.PubMedCrossRef
30.
• Windak A, Gryglewska B, Tomasik T, Narkiewicz K, Yaphe J, Grodzicki T. Competence of Polish primary-care doctors in the pharmacological treatment of hypertension. J Eval Clin Pract. 2010;16:25–30. The authors present the problem with compliance and therapeutic inertia in Poland. PubMedCrossRef
31.
• Kobalava ZD, Kotovskaya YV, Villevalde SV, Moiseev VS; ARGUS-2 Study. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study. Curr Med Res Opin. 2009;25:2229–37. The authors present the data on management of hypertension in Russia. PubMedCrossRef
32.
Bajraktari G, Sylejmani X, Thaçi K, Elezi S, Ndrepepa G. The quality of arterial hypertension treatment in cardiology service in Kosovo—a single center study—Original Investigation. Anadolu Kardiyol Derg 2009; 9: 96–101PubMed
33.
Kumpusalo E, Parnanen H, Takala J. Treatment situation of hypertensive patients in Finnish primary health care. Blood Press 1997; 1 (Suppl): 35–9.
34.
Cuspidi C, Lonati L, Sampieri L, Macca G, Valagussa L, Zaro T, et al. Blood pressure control in a hypertension hospital clinic. J Hypertens 1999; 17: 835–41.PubMedCrossRef
35.
Singer GM, Izhar M, Black HR. Goal-oriented hypertension management. Translating clinical trials to practice. Hypertension 2002; 40: 464–9.PubMedCrossRef
36.
Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957–63.PubMedCrossRef
37.
Coca A. Actual blood pressure control: are we doing things right? J Hypertens 1998; 16 (Suppl1): S45–S51.
38.
Bulpitt CJ, Fletcher AE. Prognostic significance of blood pressure in the very old. Implications for the treatment decision. Drugs Aging. 1994;5: 184–191.PubMedCrossRef
39.
Verdecchia P, Gentile G, Angeli F, Reboldi G. Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. Pol Arch Med Wewn, 2008; 118: 513–516PubMed
40.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008; 336: 1121-1123.CrossRef
41.
Beckett N, Peters R, Fletcher AE et al. for the HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887–1898PubMedCrossRef
42.
JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005; 91 (Suppl 5): v1–v52.
43.
Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999; 354: 1751–1756.PubMedCrossRef
44.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–2997.
45.
Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21: 875–886.PubMedCrossRef
46.
Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004; 44: 1175–1180PubMed
47.
Fagard RH, Van Den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002; 20: 1297–1302.PubMedCrossRef
48.
Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002; 20: 1461–1464.PubMedCrossRef
49.
• Banach M, Kjeldsen SE, Narkiewicz K. Controversies in Hypertension Treatment. Curr Vasc Pharmacol 2010; 8:731–2. The authors present the current problems in the diagnosis, control, management, treatment, and prevention of hypertension complications in hypertensive patients. PubMedCrossRef
50.
• Gaciong Z, Symonides B. Hypertension 2010: What was New for the Cardiologist? Expert Opin Pharmacother 2010; 11:2579–97. The authors present the current achievements in hypertension management in 2010, including the current guidelines of the European Society of Hypertension. PubMedCrossRef
51.
Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010;106:221–7.PubMedCrossRef
52.
Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010; 8:733–41.PubMedCrossRef
53.
Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010; 8:747–52.PubMedCrossRef
54.
Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009; 5: 3–9.
55.
Banach M, Rysz J. Current Problems in Hypertension and Nephrology. Expert Opin Pharmacother 2010; 11:2575–8.PubMedCrossRef
Metadata
Title
The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe
Authors
Agata Bielecka-Dabrowa
Wilbert S. Aronow
Jacek Rysz
Maciej Banach
Publication date
01-04-2011
Publisher
Current Science Inc.
Published in
Current Cardiovascular Risk Reports / Issue 2/2011
Print ISSN: 1932-9520
Electronic ISSN: 1932-9563
DOI
https://doi.org/10.1007/s12170-010-0152-2

Other articles of this Issue 2/2011

Current Cardiovascular Risk Reports 2/2011 Go to the issue

ReviewPaper

Obesity, Age, and Cardiac Risk

ReviewPaper

Weight Loss Drugs and Cardiovascular Risks

ReviewPaper

Cocoa Consumption, Cocoa Flavonoids, and Effects on Cardiovascular Risk Factors: An Evidence-Based Review

ReviewPaper

Salt Restriction and Challenges in China for Hypertension Control

ReviewPaper

Carotid Intima Media Thickness Versus Carotid Plaque in Cardiovascular Risk Evaluation

ReviewPaper

Does the 9p21 Genetic Variant Have a Role in Cardiovascular Risk Prediction?